UPDATE 3-AbbVie forges deeper into cancer, as clock ticks for Humira

April 28 (Reuters) - AbbVie Inc placed another big

bet on new cancer drugs on Thursday with a $5.8 billion

acquisition that could lessen its dependence on arthritis

treatment Humira, the world's top selling drug.

Read more